Edition:
India

Aytu Bioscience - On Nov 2, 2018, Co Entered Into A License, Development, Manufacturing And Supply Agreement With Tris Pharma - SEC Filing


Monday, 5 Nov 2018 

Aytu BioScience Inc ::AYTU BIOSCIENCE - ON NOV 2, 2018, CO ENTERED INTO A LICENSE, DEVELOPMENT, MANUFACTURING AND SUPPLY AGREEMENT WITH TRIS PHARMA - SEC FILING.AYTU BIOSCIENCE - AS PER AGREEMENT, TRIS GRANTED TO CO AN EXCLUSIVE LICENSE IN UNITED STATES RELATED TO TUZISTRA XR.AYTU BIOSCIENCE INC - ALONG WITH TUZISTRA XR, CO HAS LICENSED A COMPLEMENTARY ANTITUSSIVE PRODUCT PENDING FDA APPROVAL.AYTU BIOSCIENCE INC - AS PART OF TRANSACTION, CO ALSO PLANS TO ENTER INTO A STRATEGIC FINANCING WITH ARMISTICE CAPITAL, LLC.AYTU BIOSCIENCE - UNDER TERMS OF FINANCING, ARMISTICE EXPECTED TO PROVIDE CO WITH UP TO $5 MILLION IN FORM OF 3 YEAR NOTE, SECURED BY TUZISTRA REVENUE STREAMS.AYTU BIOSCIENCE - CO WILL PAY TRIS PHARMA MILESTONE PAYMENTS AND CERTAIN ROYALTY FEES THROUGH TERM FOR TUZISTRA XR AND CCP-08. 

Company Quote

0.8047
-0.0153 -1.87%
24 Jan 2020